by Mybiogate | Feb 25, 2021 | China Market
Author: HE Sheng Recently the CDK4/6 inhibitor Cosela (trilaciclib), developed by G1Therapeutics, was launched in the United States. The inhibitor’s aim is to “decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered... by Mybiogate | Jan 4, 2021 | China Market
Author: HE Sheng In China, licensing in has become a key link in the new drug research and development industry chain. Licensing is when one company gives another company permission for a specific period of time to manufacture its product in return for an... by Mybiogate | Dec 8, 2020 | China Market
Author: HE Sheng Recently, the Hurun Research Institute released their list of “Hurun’s 2020 Top Chinese 500 Private Enterprises”, ranked according to the companies’ market value or valuation. The market value of listed companies is calculated based on...
by Mybiogate | Dec 8, 2020 | China Market
by Mybiogate | Dec 3, 2020 | China Market
Author: MyBioGate December 1, 2020 is the 33rd “World AIDS Day” with the theme: “Ending the HIV/AIDS Epidemic: Resilience and Impact”. Today we will take a brief look current AIDS treatment drugs, the market, and the progress of research... by vivek | Sep 27, 2020 | China Market
China has a long history with ophthalmology, eye care, through traditional Chinese medicine practices, but as technology advances, so must research and medical practices to ensure that the best and most successful treatments possible are available. In the past,...